| Generic name | Ofatumumab |
| Pronunciation | oh-fah-TOO-moo-mab |
| Brand name(s), other common name(s) | Arzerra® |
| Drug type | Monoclonal antibody |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Ofatumumab is FDA approved
- For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
- For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
- In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.
Side effects needing medical attention
Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
In patients with prior hepatitis B (HBV) infection, HBV reactivation may occur when the body's immune system is impaired.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.